复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02196 复星医药

已收盘 05-27 16:09:08

16.980

-0.270

-1.57%

最高17.290	最低16.850	成交量313.70万
今开17.280	昨收17.250	日振幅2.55%
总市值451.50亿	流通市值91.86亿	总股本26.59亿
成交额5,331万	换手率0.58%	流通股本5.41亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02196","market":"HK","secType":"STK","nameCN":"复星医药","latestPrice":16.98,"timestamp":1779869348004,"preClose":17.25,"halted":0,"volume":3137000,"delay":0,"changeRate":-0.015652173913043455,"floatShares":540971500,"shares":2659000000,"eps":1.4672880253828977,"marketStatus":"已收盘","change":-0.27,"latestTime":"05-27 16:09:08","open":17.28,"high":17.29,"low":16.85,"amount":53308737,"amplitude":0.025507,"askPrice":16.98,"askSize":500,"bidPrice":16.97,"bidSize":16000,"shortable":3,"etf":0,"ttmEps":1.5133423838614908,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1779931800000},"marketStatusCode":5,"adr":0,"listingDate":1351526400000,"exchange":"SEHK","adjPreClose":17.25,"dividendRate":0.020612,"openAndCloseTimeList":[[1779845400000,1779854400000],[1779858000000,1779868800000]],"volumeRatio":1.521162,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600196","market":"SH","secType":"STK","nameCN":"复星医药","latestPrice":23.32,"timestamp":1779865200000,"preClose":23.17,"halted":0,"volume":22754100,"delay":0,"premium":"-36.98"}},"requestUrl":"/m/hq/s/02196","defaultTab":"news","newsList":[{"id":"2638245485","title":"复星医药子公司拟参投星曜坤泽，后者尚无产品上市，去年1至10月亏损1808万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2638245485","media":"深圳商报·读创","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638245485?lang=zh_cn&edition=full","pubTime":"2026-05-27 08:52","pubTimestamp":1779843140,"startTime":"0","endTime":"0","summary":"5月26日晚间，复星医药（600196）发布公告称，公司控股子公司复星医药产业拟出资共计4.14亿元与其他新投资方共同参与星曜坤泽B轮融资并受让本公司联营公司苏州基金、天津基金所持有的星曜坤泽（下称“标的公司”）部分股权。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605273750375029.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0187","BK0028","BK0060","BK1593","IPOS","BK0096","BK0175","02196","BK0188","BK0012","BK1515","BK0183","BK0196","BK0239","BK1191","600196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638438235","title":"复星医药（600196）披露对外投资暨关联交易公告，5月26日股价下跌0.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2638438235","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638438235?lang=zh_cn&edition=full","pubTime":"2026-05-26 22:24","pubTimestamp":1779805464,"startTime":"0","endTime":"0","summary":"截至2026年5月26日收盘，复星医药报收于23.17元，较前一交易日下跌0.56%，最新总市值为618.74亿元。近日，复星医药发布《关于对外投资暨关联交易的公告》。公告显示，公司控股子公司复星医药产业拟出资41,437.50万元参与星曜坤泽B轮融资并受让苏州基金、天津基金所持股权，其中21,781.3912万元用于认缴新增注册资本，19,656.1088万元用于受让股权。交易完成后，预计持有星曜坤泽20.8709%股权。本次投资已获董事会审议通过，无需提交股东大会批准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052600041243.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","BK0060","BK0028","BK0096","BK0012","600196","BK0183","BK0188","02196","BK0187","BK0175","BK0196","BK1191","BK1593","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638597731","title":"复星医药：控股子公司出资4.14亿元参与星曜坤泽B轮融资","url":"https://stock-news.laohu8.com/highlight/detail?id=2638597731","media":"南方财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638597731?lang=zh_cn&edition=full","pubTime":"2026-05-26 17:04","pubTimestamp":1779786240,"startTime":"0","endTime":"0","summary":"南财智讯5月26日电，复星医药公告，控股子公司上海复星医药产业发展有限公司拟出资共计人民币41437.50万元，其中21781.39万元用于认缴苏州星曜坤泽生物医药股份有限公司新增注册资本293.68万元，19656.11万元用于受让苏州基金及天津基金合计持有的星曜坤泽存续注册资本308.65万元；交易完成后，复星医药产业预计将持有星曜坤泽20.87%的股权。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605263749758734.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","BK0096","BK0183","BK0188","BK0239","600196","BK0012","BK0175","BK1515","BK0060","BK0028","BK0196","BK1593","02196","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637733973","title":"每周股票复盘：复星医药（600196）多款新药获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2637733973","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637733973?lang=zh_cn&edition=full","pubTime":"2026-05-24 02:09","pubTimestamp":1779559752,"startTime":"0","endTime":"0","summary":"截至2026年5月22日收盘，复星医药报收于23.4元，较上周的24.13元下跌3.03%。复星医药控股子公司复宏汉霖自主研发的HLX3902注射液获澳大利亚人类研究伦理委员会批准，并完成澳大利亚药品管理局备案，允许在澳开展Ⅰ期临床试验，系该药品全球首次获得临床试验许可。复星医药控股子公司重庆药友制药有限责任公司获得国家药品监督管理局批准，其左氧氟沙星注射液正式获准上市。该药品已获中国临床试验批准及澳大利亚药品管理局备案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052400000454.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","02196","BK0012","BK1593","BK0096","BK1515","BK0188","BK0183","BK0175","600196","BK0028","BK0239","BK0196","BK0187","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637381906","title":"复星医药(02196)控股子公司就左氧氟沙星注射液的药品注册申请获国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2637381906","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637381906?lang=zh_cn&edition=full","pubTime":"2026-05-21 17:50","pubTimestamp":1779357023,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药 发布公告，近日，上海复星医药(集团)股份有限公司控股子公司重庆药友制药有限责任公司就左氧氟沙星注射液的药品注册申请获国家药品监督管理局批准。截至2026年4月，本集团现阶段针对该药品的累计研发投入约为人民币194万元。根据IQVIACHPA最新数据，2025年，左氧氟沙星注射剂于中国境内的销售额约为人民币10.57亿元。该药品本次获批上市，将进一步丰富本集团产品线。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444560.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0096","BK0196","BK0012","BK0028","BK0187","02196","BK1593","BK0183","600196","BK0239","BK1191","BK1515","BK0175","BK0060","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109022016","title":"复星医药左氧氟沙星注射剂新药注册申请获中国药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1109022016","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109022016?lang=zh_cn&edition=full","pubTime":"2026-05-21 17:46","pubTimestamp":1779356798,"startTime":"0","endTime":"0","summary":"上海复星医药（集团）股份有限公司宣布，其提交的左氧氟沙星注射剂新药注册申请，已获得中国国家药品监督管理局的正式批准。这一进展标志着该产品在中国市场上市销售的关键监管障碍已被清除。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02196","600196","BK0175","BK0012","BK1191","BK0028","BK1515","BK0096","BK0188","BK0183","BK1593","BK0196","BK0060","BK0187","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637386195","title":"复星医药(600196.SH)子公司HLX3902注射液获准于澳大利亚开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2637386195","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637386195?lang=zh_cn&edition=full","pubTime":"2026-05-21 16:47","pubTimestamp":1779353268,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(600196.SH)发布公告，近日，公司控股子公司上海复宏汉霖生物技术股份有限公司及其控股子公司(合称“复宏汉霖”)自主研发的HLX3902注射液(即STEAP1xCD3xCD28三特异性抗体)用于转移性去势抵抗性前列腺癌及其他晚期实体瘤治疗的Ⅰ期临床试验方案获得相关人类研究伦理委员会的批准、并通过澳大利亚药品管理局(Therapeutic Goods Administration)备案，系该药品于全球范围内取得的首个临床试验许可。复宏汉霖拟于条件具备后于澳大利亚开展该药品的相关临床研究。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444492.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0012","BK0060","BK0187","BK0096","BK0196","BK0175","BK0188","BK1515","BK0239","BK0183","BK0028","BK1593","02196","600196","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636849445","title":"复星医药：截至2026年5月20日本集团无逾期担保事项","url":"https://stock-news.laohu8.com/highlight/detail?id=2636849445","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636849445?lang=zh_cn&edition=full","pubTime":"2026-05-20 18:54","pubTimestamp":1779274440,"startTime":"0","endTime":"0","summary":"5月20日，复星医药发布公告称，截至2026年5月20日，包括本次担保在内，本集团实际对外担保金额折合人民币约2，121，217万元，约占2025年12月31日本集团经审计的归属于上市公司股东净资产的43.52%；均为本公司与控股子公司/单位之间、控股子公司/单位之间发生的担保。截至2026年5月20日，本集团无逾期担保事项。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605203743672945.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0012","BK0096","600196","BK0187","BK0183","02196","BK0060","BK0188","BK0028","BK0196","BK1515","BK1593","BK0175","BK1191","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636061617","title":"每周股票复盘：复星医药（600196）获阿尔茨海默病新药全球开发选择权","url":"https://stock-news.laohu8.com/highlight/detail?id=2636061617","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636061617?lang=zh_cn&edition=full","pubTime":"2026-05-17 01:56","pubTimestamp":1778954171,"startTime":"0","endTime":"0","summary":"截至2026年5月15日收盘，复星医药报收于24.13元，较上周的24.82元下跌2.78%。本周，复星医药5月12日盘中最高价报25.62元。本周关注点来自公司公告汇总：复星医药产业获授AR1001分子用于治疗阿尔茨海默病的全球多中心III期临床试验后90天内独家选择权。来自公司公告汇总：复星医药控股子公司桃红四物汤颗粒注册申请获国家药监局受理。协议涉及选择权费6000万美元，后续首付款及里程碑付款最高达1.8亿美元，另按销售分成支付。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051700000399.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1191","02196","BK0028","BK1515","BK0175","BK0239","BK0183","BK0060","600196","BK0188","BK0196","BK1593","BK0096","BK0012","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635208430","title":"复星医药：公司开展许可类交易遵循市场化规律","url":"https://stock-news.laohu8.com/highlight/detail?id=2635208430","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635208430?lang=zh_cn&edition=full","pubTime":"2026-05-15 20:00","pubTimestamp":1778846400,"startTime":"0","endTime":"0","summary":"证券日报网讯5月15日，复星医药在互动平台回答投资者提问时表示，公司开展许可类交易遵循市场化规律，近年来开展的重大许可交易的对方均非大股东及其关联方。如后续涉及关联交易，公司会遵照相关法律法规及股票上市地监管要求，履行必要的前置评估/估值程序，根据《公司章程》提请相应的审批机构审议，并依照股票上市地规则进行相应披露。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605153739146511.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0028","600196","BK0096","BK0196","02196","BK1515","BK0060","BK0183","BK1593","BK0012","BK1191","BK0187","BK0175","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635083481","title":"复星医药：星曜坤泽系由公司联营公司复健资本旗下基金所孵化的企业","url":"https://stock-news.laohu8.com/highlight/detail?id=2635083481","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635083481?lang=zh_cn&edition=full","pubTime":"2026-05-15 18:12","pubTimestamp":1778839954,"startTime":"0","endTime":"0","summary":"每经AI快讯，有投资者在投资者互动平台提问：您好，尊敬的复兴医药董秘。我是复兴医药的一名普通投资者，请问贵公司与苏州星耀坤泽是否有关联？有的话占比多少？该公司现在101及102药物研发进展如何？","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605153739069829.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605153739069829.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0183","BK0060","BK1593","02196","BK1191","BK0012","BK0096","BK0028","BK1515","600196","BK0188","BK0239","BK0196","BK0175","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635908882","title":"复星医药：目前控股子公司复宏汉霖已收到与Eisai合作项下的首付现金款","url":"https://stock-news.laohu8.com/highlight/detail?id=2635908882","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635908882?lang=zh_cn&edition=full","pubTime":"2026-05-15 17:47","pubTimestamp":1778838457,"startTime":"0","endTime":"0","summary":"每经AI快讯，有投资者在投资者互动平台提问：董秘您好，请问：复宏汉霖2026年2月授权卫材的7500万美元首付款，在复星医药2026年一季度合并报表中，是否已确认为当期收入？谢谢。复星医药（600196.SH）5月15日在投资者互动平台表示，截至目前，控股子公司复宏汉霖已收到与Eisai合作项下的首付现金款，并根据会计准则进行会计处理。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605153739043716.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605153739043716.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02696","BK0096","BK1191","BK0028","BK1593","HK0000320223.HKD","BK0239","HK0000306685.HKD","HK0000306701.USD","BK0187","BK0060","600196","BK0188","HK0000165453.HKD","BK0012","BK1161","BK0183","BK0175","HK0000320264.USD","BK0196","BK1515","02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635743879","title":"复星医药再加码阿尔茨海默病口服药，预计年内出三期数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2635743879","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635743879?lang=zh_cn&edition=full","pubTime":"2026-05-14 21:33","pubTimestamp":1778765580,"startTime":"0","endTime":"0","summary":"“昨天我们刚刚达成协议，今天早上双方团队开始融合了，会以更大的投入来加速整体的完成速度。全球加起来有十几个国家参与，200多个不同的医院参与，所以整个数据清理需要花一点时间，预计今年9-10月份可能出三期数据，到年底，也许能知道这个药是否可以递交NDA（新药申请）。”5月14日，复星医药（600196.SH，2196.HK）联席总裁王兴利在媒体沟通会上透露了上述消息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605143737752528.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605143737752528.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0188","BK0096","BK0239","BK1191","BK0028","BK0012","BK0196","BK1515","BK0183","BK1593","02196","BK0187","BK0060","600196","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635171861","title":"复星医药的“聪明Deal”：6000万美元锁住AR1001超25亿美元想象空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2635171861","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635171861?lang=zh_cn&edition=full","pubTime":"2026-05-14 17:44","pubTimestamp":1778751861,"startTime":"0","endTime":"0","summary":"然而，复星医药选择的AR1001走了一条差异化的道路——小分子口服药物。复星医药本次先向AriBio支付6000万美元的选择权费，这笔钱买的是“看涨期权”，复星医药拥有一个约定的行权窗口期，可以在这段时间内从容等待AR1001的全球III期临床试验顶线结果。一旦III期结果积极，选择行权，此时再支付8000万美元的首付款，等到上市，再支付1亿美元的监管里程碑付款。这一次，复星医药拿下的不仅是“卖药的权利”，赢得认可的更是“造药出海的能力”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1441768.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0183","BK0028","BK0239","02196","BK1593","BK0196","BK0187","BK1191","BK0012","BK0175","BK0188","BK0060","600196","BK1515","BK0096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635754092","title":"智通港股早知道 | 中国AI用电料大增 算电协同受关注","url":"https://stock-news.laohu8.com/highlight/detail?id=2635754092","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635754092?lang=zh_cn&edition=full","pubTime":"2026-05-14 07:21","pubTimestamp":1778714476,"startTime":"0","endTime":"0","summary":"中国AI用电料大增 算电协同受关注随着《关于促进人工智能与能源双向赋能的行动方案》正式落地，政策与市场形成强力共振，算电协同从产业概念加速转向实体落地。瑞银研报显示，尤其是2028年，AI用电量较2027年同比大增75%，出现大幅度跃升，此后2029年与2030年增速虽有所回落，但仍有50%与40%的增长。归属于普通股股东的净利润为人民币254.76亿元。净利润为人民币 1021.27 亿元，同比下降19%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1441475.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0211977185.USD","LU0345776255.USD","LU0080751232.USD","LU1235295612.USD","LU0345775950.USD","LU2097828474.EUR","SG9999018857.SGD","LU0228367735.SGD","LU0327786744.USD","LU0348784397.USD","LU0499858438.USD","IE00BGV7N243.SGD","LU1226288170.HKD","IE00B8HQ1Z84.USD","LU2177674079.SGD","LU1504937902.USD","HK0000306701.USD","LU2476274308.USD","LU2294711473.HKD","SGXZ31699556.SGD","LU1282649141.HKD","LU2125910500.SGD","01070","SGXZ90724238.SGD","LU0210527791.USD","LU0214875030.USD","LU1868837722.USD","LU0463099449.HKD","03813","BK4588","LU0067412154.USD","LU0048388663.USD","LU0886674414.USD","LU0264606111.USD","IE0031814852.USD","LU1196710195.USD","LU0196878994.USD","LU0880133367.SGD","LU0831103253.SGD","LU0228659784.USD","SG9999014674.SGD","LU0029875118.USD","LU1785774172.SGD","LU0326948709.USD","LU0572939691.SGD","IE00B0169L03.USD","TCEHY","LU0320764599.SGD","LU0061477393.USD","LU0918141887.USD","LU0862451837.USD","LU1105468828.SGD","SG9999001903.USD","LU0821914370.USD","LU0823413587.USD","SGXZ81514606.USD","LU1152091754.HKD","SG9999006514.SGD","LU1044876610.USD","LU0287142896.SGD","BK1502","LU0531971595.HKD","LU0210526637.USD","LU0509642566.USD","LU1794554557.SGD","LU1044874839.SGD","SG9999006597.SGD","LU1917777945.USD","LU2257852520.SGD","LU2317271919.USD","LU0873338254.USD","SG9999007991.SGD","LU0823040885.USD","LU0648948544.HKD","LU0456827905.SGD","LU1188198961.HKD","BK1591","LU2399975544.HKD","LU0370786039.SGD","LU0828237510.HKD","BK4585","SG9999015945.SGD","LU1688375341.USD","LU2237443622.USD","IE00B067MR52.USD","LU0594300179.USD","LU0169518387.USD","LU0611395673.USD","LU1515016050.SGD","LU0431992006.USD","LU0501845795.SGD","LU0588545490.SGD","LU0348735423.USD","LU1226287875.USD","LU0593848301.USD","BABA","LU0054450605.USD","LU1282648689.USD","LU0589944569.HKD","LU0449515922.USD","LU0577902298.EUR","LU1226288097.SGD","LU0315179316.USD","LU0791591158.USD","LU2106854487.HKD","LU0049112450.USD","SG9999013353.USD","LU0594300419.USD","LU1956131251.USD","LU0672654166.SGD","LU0314109678.HKD","LU0675040207.SGD","LU0862451753.SGD","LU0106259558.USD","LU0348783233.USD","LU0163747925.USD","SG9999003461.SGD","LU0149721374.USD","LU0577902538.SGD","LU0417516571.SGD","BK1586","HK0000320264.USD","LU0516423091.SGD","LU1226287529.USD","LU0572944931.SGD","LU2237443549.SGD","BK1526","LU0819123356.HKD","LU0456846285.SGD","LU0307460666.USD","LU0823426480.USD","IE00BZ08YT58.USD","BK1615","LU1251922891.USD","LU0259732245.USD","LU0149534421.HKD","LU0608807946.USD","IE0008369823.USD","LU0048580855.USD","LU1064130708.USD","03700","LU0229945570.USD","SG9999001051.SGD","IE00BF5LJ272.USD","LU0188438112.USD","LU0128522157.USD","IE00B031HW06.USD","LU1720050803.USD","BK1608","LU0588545904.SGD","LU0165289439.USD","06936","IE0003795394.USD","LU1102505762.USD","BK1521","LU0329678337.USD","TSLA","LU0106959298.USD","LU3063872942.SGD","LU0449509016.USD","LU0029874905.USD","LU0348783662.USD","LU2265009873.SGD","LU0890818403.SGD","LU1226287792.SGD","IE00BQXX3C00.GBP","LU1439102457.SGD","LU0070217475.USD","LU0127658192.USD","LU0708995153.HKD","LU0203347892.USD","LU0047713382.USD","LU1770036033.HKD","HK0000914660.USD","BK1610","LU0572940350.SGD","LU1196710864.SGD","LU0164872284.USD","SG9999001226.SGD","LU0164865239.USD","LU0254981946.USD","IE0008368742.USD","NVDA","LU0823041008.USD","LU0244354667.USD","LU2097828631.EUR","LU1008478684.HKD","BK1618","LU0541502299.USD","LU0417516738.SGD","BK1589","LU0128522744.USD","LU0823038988.USD","LU0348805143.USD","HK0001040168.HKD","LU0683595622.HKD","GOOGL","LU0072462343.USD","LU0132412106.USD","LU0396098781.USD","LU1048484197.HKD","LU2039709279.SGD","SG9999015978.USD","LU1226288253.USD","LU2362540622.SGD","LU0348723411.USD","LU1048588211.SGD","SG9999001069.SGD","IE0003851619.USD","LU0326950275.SGD","LU0791590937.USD","LU0979878070.USD","LU2237443895.HKD","LU1810669033.SGD","LU1568876335.HKD","IE00B0169N27.USD","LU0737861772.HKD","LU1981816686.USD","LU0320764243.SGD","IE00B8L5B284.USD","LU0543330566.HKD","LU1880383440.USD","LU2008162690.USD","SG9999017495.SGD","LU2251237306.USD","SG9999000327.SGD","LU0345769631.USD","LU1691799644.USD","LU1568876251.USD","LU2279701549.SGD","LU0737861699.HKD","LU0786609619.USD","LU0499858602.USD","LU1316542783.SGD","LU0329678170.USD","SG9999004220.SGD","LU1282649067.USD","LU2778985437.USD","LU0106252389.USD","LU0143863198.USD","LU0856984785.SGD","LU2087589342.USD","LU0072913022.USD","SG9999014906.USD","LU0348816934.USD","IE0008368411.USD","LU2097828557.USD","LU0084288322.USD","LU0320764755.SGD","HK0000320223.HKD","LU1242518857.USD","HTCD.SI","LU0143863784.USD","LU1323998911.USD","LU2148510915.USD","LU0865486749.SGD","LU1064131003.USD","LU0823039010.USD","LU0823397103.USD","BK1557","SG9999014914.USD","LU0651946864.USD","LU2097828714.EUR","LU0441854154.USD","LU0871576103.HKD","LU1044875133.USD","LU1814569148.SGD","LU0048597586.USD","LU0359201885.HKD","LU1807302812.USD","IE00BZ08YS42.EUR","LU1974910355.USD","IE0034224299.USD","SG9999001846.SGD","LU0210533765.USD","SG9999000418.SGD","HK0001040143.USD","LU0541501648.USD","LU0633140560.USD","BK1114","LU2362541273.HKD","LU0738912210.USD","GB00BDT5M118.USD","LU0117844026.USD","LU0878004406.USD","LU2237443465.HKD","LU1868838027.USD","LU2051468812.USD","SGXZ51526630.SGD","SG9999002828.SGD","LU1961090484.USD","LU0531970944.HKD","LU1719994722.HKD","LU1051769294.HKD","LU0784639295.USD","LU1725190679.HKD","SG9999001093.SGD","IE0032431581.USD","LU0650527681.SGD","LU1883866441.USD","LU1718418525.SGD","LU0700851271.USD","00659","BK1609","IE00BQXX3F31.USD","LU0828237940.HKD","IE00B543WZ88.USD","LU0096374516.USD","LU2251237488.HKD","LU1366334578.USD","LU0882747503.HKD","IE0003895053.USD","LU1960683339.HKD","SG9999002463.SGD","HK0000352291.HKD","LU0642271901.SGD","LU2449936058.SGD","LU1282651048.USD","LU0173614495.USD","SG9999002562.SGD","SGXZ99366536.SGD","LU0605514214.HKD","LU0588546209.SGD","IE00B3M56506.USD","LU0417516902.SGD","LU2097828805.USD","02196","IE00B031HY20.USD","LU0633140727.USD","LU1048596156.SGD","LU0140636845.USD","LU1769817179.HKD","LU2247934214.USD","LU0543330483.HKD","LU0972618739.USD","LU2133065610.SGD","LU0231483743.USD","NWSGY","LU1328277881.USD","LU0878005551.USD","LU0985320562.USD","00700","LU1993786604.SGD","09988","LU0348827113.USD","LU1655091459.SGD","LU1733274390.USD","SG9999001689.USD","IE0009570106.USD","LU0315178854.USD","LU0607220059.USD","LU0348825331.USD","LU0918141705.HKD","TCHmain","LU1303224171.USD","LU1868837565.USD","IE00BZ08YR35.GBP","LU2237443978.SGD","LU0608807433.USD","LU1196710351.USD","LU2293587155.HKD","LU1242518931.SGD","LU1808992512.USD","LU1770034418.SGD","IE00BQXX3D17.EUR","META","BK1095","LU2476274720.SGD","LU0049853897.USD","LU1675838814.USD","LU0828238088.HKD","LU2242644610.SGD","LU0488056044.USD","LU0823397285.USD","LU2462611646.USD","LU0823426308.USD","LU0164880469.USD","LU0203345920.USD","LU0540923850.HKD","BK1096","HK0000352382.USD","LU0898667661.SGD","LU0588545730.USD","LU2152927971.USD","LU0261950983.USD","LU1211504680.USD","LU0516422366.SGD","LU1051768304.USD","LU2498475776.HKD","LU1366334651.USD","LU0516422440.USD","LU0348814723.USD","LU1733274473.HKD","IE00B0JY6N72.USD","LU0181495838.USD","BK1531","LU2125910849.SGD","LU1734074674.USD","BK1516","IE0001KFT4U8.USD","LU0192582467.USD","LU0235996351.USD","LU1439103000.SGD","LU1642822792.SGD","LU0054237671.USD","LU1951186391.HKD","LU0251144936.SGD","LU0261947096.USD","LU1629966141.USD","LU1813983027.USD","LU0117841782.USD","LU0561508036.HKD","SG9999014880.SGD","LU0577902454.USD","LU0345769128.USD","IE00B031J352.USD","SG9999014898.SGD","IE00B97KM107.HKD","LU2023250504.SGD","LU0348788117.USD","LU1328615791.USD","LU0175139822.USD","LU0502904849.HKD","LU0328353924.USD","LU0289960550.SGD","LU0293314216.USD","LU1804176565.USD","LU0414403682.SGD","LU0107464264.USD","LU0269904917.USD","LU0359202008.SGD","SG9999015952.SGD","LU0384037296.USD","LU2237443382.USD","LU1282649810.SGD","LU0797268264.HKD","LU1282651121.HKD","LU0011963245.USD","LU1769817096.USD","LU1152091168.USD","HK0000151867.HKD","SG9999015986.USD","LU1880383366.USD","LU0868486357.SGD","LU2226246903.HKD","600196","LU0651947912.USD","IE00B29SXG58.USD","LU0456842615.SGD","LU0043850808.USD","LU0634319403.HKD","LU0577902611.USD","HK0000306685.HKD","LU1224709979.USD","SG9999000459.SGD","IE00B5MMRT66.SGD","LU0455707207.USD","LU1481107354.HKD","LU1224444064.USD","LU1023057109.AUD","LU1046422090.SGD","IE00BPRC5H50.USD","LU0051755006.USD","LU0359201612.USD","LU0708995583.HKD","HK0000914686.HKD","LU0039217434.USD","002352","LU2362541513.USD","LU2045819591.USD","LU0516422952.EUR","LU0577902371.SGD","LU0469268626.HKD","LU0516423174.USD","LU0823413660.USD","BK1517","IE0032834883.USD","LU0819121731.USD","LU1102505929.USD","SG9999018865.SGD","LU1831875114.USD","LU0052750758.USD","LU0211331839.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635542847","title":"国家医保局：持续创新拓展“人工智能+医保监管”的实践路径和应用场景；复星医药控股子公司获AriBio授予独家选择权丨医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2635542847","media":"每日经济新闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635542847?lang=zh_cn&edition=full","pubTime":"2026-05-14 07:04","pubTimestamp":1778713480,"startTime":"0","endTime":"0","summary":"丨2026年5月14日星期四丨NO.1国家医保局：持续创新拓展“人工智能+医保监管”的实践路径和应用场景5月13日，国家医疗保障局印发《医疗保障基金监督检查五年行动计划（2026年—2030年）》。行动计划提出，聚焦人工智能赋能，持续创新拓展“人工智能+医保监管”的实践路径和应用场景。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605143736403322.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605143736403322.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02196","161631","BK0239","BK0096","ARTY","BK0196","AGIX","BK0175","BK0012","BK0187","BK1191","BK1515","BK0183","600196","09939","CHAT","BK1161","BK0028","BK1593","BK0188","BK0060","159938","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635057789","title":"复星医药(02196)：桃红四物汤颗粒的药品注册申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2635057789","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635057789?lang=zh_cn&edition=full","pubTime":"2026-05-13 19:30","pubTimestamp":1778671817,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药 发布公告，近日，上海复星医药(集团)股份有限公司控股子公司河北万邦复临药业有限公司就桃红四物汤颗粒的药品注册申请获国家药品监督管理局受理。截至本公告日期，仅两款桃红四物汤颗粒于中国境内获批上市，获批时间分别为2025年4月、2026年4月，目前尚未能从IQVIA CHPA查询到该等药品2025年于中国境内的销售额。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1441355.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02196","BK0096","BK1191","BK0012","BK1593","BK0188","BK0060","BK0183","BK0239","BK0196","BK1515","BK0187","BK0028","600196","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184425360","title":"复星医药旗下桃红四物汤颗粒药品注册申请获中国药监局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=1184425360","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184425360?lang=zh_cn&edition=full","pubTime":"2026-05-13 19:27","pubTimestamp":1778671633,"startTime":"0","endTime":"0","summary":"复星医药旗下单位提交的桃红四物汤颗粒药品注册申请，已获得中国国家药品监督管理局正式受理。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0060","BK0188","BK1191","BK0187","BK0239","600196","BK0196","BK1515","02196","BK0012","BK0175","BK0028","BK0096","BK1593","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635785407","title":"复星医药最新公告：控股子公司复星医药产业获AriBio授予独家选择权","url":"https://stock-news.laohu8.com/highlight/detail?id=2635785407","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635785407?lang=zh_cn&edition=full","pubTime":"2026-05-13 18:51","pubTimestamp":1778669467,"startTime":"0","endTime":"0","summary":"复星医药(600196.SH)公告称，控股子公司复星医药产业与AriBio签订独家选择权协议，获授许可产品AR1001(用于治疗早期阿尔茨海默病)的全球多中心III期临床试验完成后90天内决定是否行权的权利。如行权，将获授权在全球范围(特定区域除外)独家开发、注册、生产及商业化该药物。复星医药产业需支付6000万美元选择权费，行权后另付至多1.8亿美元首付款及监碑款项。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051300035413.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1593","BK0060","BK0012","BK0028","BK0175","BK0096","02196","BK0196","BK1191","BK0183","600196","BK0239","BK0187","BK1515","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130185682","title":"复星医药将回购不超过已发行股份10%的股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1130185682","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130185682?lang=zh_cn&edition=full","pubTime":"2026-05-11 16:46","pubTimestamp":1778489186,"startTime":"0","endTime":"0","summary":"上海复星医药（集团）股份有限公司于香港联合交易所有限公司及上海证券交易所上市，日前发布公告称，董事会已审议通过关于授权回购A股及H股股份的相关议案，并将于2026年6月16日召开股东周年大会，提交股东审议。根据公告，本次授权最高可回购公司于批准当日已发行A股股份及H股股份各10%。回购授权将在股东周年大会及A股、H股类别股东会上表决，授权期间将持续至下届股东周年大会结束或相关决议被撤销或修订之日止。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"复星医药将回购不超过已发行股份10%的股份","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02196"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.fosunpharma.com","stockEarnings":[{"period":"1week","weight":-0.0298},{"period":"1month","weight":-0.1435},{"period":"3month","weight":-0.1577},{"period":"6month","weight":-0.1894},{"period":"1year","weight":0.2456},{"period":"ytd","weight":-0.1176}],"compareEarnings":[{"period":"1week","weight":-0.0077},{"period":"1month","weight":-0.0146},{"period":"3month","weight":-0.0436},{"period":"6month","weight":-0.0134},{"period":"1year","weight":0.0995},{"period":"ytd","weight":-0.0012}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海复星医药（集团）股份有限公司是一家主要从事医药产品研发、制造与销售的中国公司。该公司经营五个分部。制药分部主要从事创新药、成熟医药产品制造和疫苗业务。医疗器械与医学诊断分部主要从事分子诊断、免疫诊断、微生物诊断等医疗美容器械的制造和销售。医疗健康服务分部主要从事线上线下一体化医疗服务平台的经营。医药分销和零售分部主要从事医药产品的批发零售。其他分部从事其他医药相关业务。该公司的产品主要用于肿瘤、免疫、中枢神经等治疗领域。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.044492},{"month":2,"riseRate":0.714286,"avgChangeRate":0.036178},{"month":3,"riseRate":0.571429,"avgChangeRate":0.044258},{"month":4,"riseRate":0.357143,"avgChangeRate":0.026005},{"month":5,"riseRate":0.428571,"avgChangeRate":0.025794},{"month":6,"riseRate":0.461538,"avgChangeRate":-0.026545},{"month":7,"riseRate":0.615385,"avgChangeRate":0.027595},{"month":8,"riseRate":0.307692,"avgChangeRate":-0.041651},{"month":9,"riseRate":0.461538,"avgChangeRate":0.011609},{"month":10,"riseRate":0.461538,"avgChangeRate":0.020359},{"month":11,"riseRate":0.428571,"avgChangeRate":0.034495},{"month":12,"riseRate":0.428571,"avgChangeRate":0.015123}],"exchange":"SEHK","name":"复星医药","nameEN":"FOSUN PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供复星医药(02196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"复星医药,02196,复星医药股票,复星医药股票老虎,复星医药股票老虎国际,复星医药行情,复星医药股票行情,复星医药股价,复星医药股市,复星医药股票价格,复星医药股票交易,复星医药股票购买,复星医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供复星医药(02196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}